Elutia Inc. Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Date: March 11, 2026

Key Highlights for Investors

• Regulatory Milestone: Elutia submitted its 510(k) application for the base biologic matrix, NXT-41, to the FDA. The company anticipates FDA clearance in the second half of 2026 and full clearance for NXT-41x, the antibiotic-eluting version, in the first half of 2027.
• Focus on Breast Cancer Surgery Market: NXT-41x targets the \$1.5 billion U.S. breast cancer surgery market, where post-operative infection rates remain high (15-20%). Surgeon engagement and feedback have been positive, reinforcing the product’s market potential.
• Leadership and Commercial Team Expansion: The company strengthened its board and executive team, adding Guido J. Neels (EW Healthcare Partners, ex-Guidant COO) to the board and Pete Ligotti (former Integra Life Sciences) as Chief Commercial Officer to drive commercialization and launch readiness for NXT-41x.
• Strategic Divestiture and Capital Infusion: On October 1, 2025, Elutia completed the \$88 million sale of its EluPro™ and CanGaroo BioEnvelope businesses to Boston Scientific Corporation. This transaction validated Elutia’s drug-eluting biologics platform and provided significant capital to fund NXT-41x development and commercialization.
• Debt Repayment and Balance Sheet Transformation: The company used the proceeds to repay the entire \$26.9 million outstanding debt facility with SWK Holdings, further strengthening its balance sheet.
• Cash Position: As of December 31, 2025, Elutia reported \$36.4 million in cash, with an additional \$8.0 million in escrow from the BioEnvelope divestiture expected to be released in Q4 2026.
• SimpliDerm Strategic Review: The company has initiated a process to explore strategic options for its patented SimpliDerm product line, aiming straps its resources on the upcoming NXT-41x launch.

Fourth Quarter 2025 Financial Results

• Net Sales: \$3.3 million (up 16% from Q4 2024).
• SimpliDerm Sales: \$2.1 million (down from \$2.3 million in Q4 2024).
• Cardiovascular Product Sales: \$1.2 million (up from \$0.5 million in Q4 2024).
• Gross Margin (GAAP): 58.5% (up from 46.9%).
• Adjusted Gross Margin (Non-GAAP): 66.8% (up from 56.5%).
• Total Operating Expenses: \$8.5 million (slightly down from \$8.8 million).
• Loss from Continuing Operations: \$6.6 million (improved from \$7.5 million).
• Net Loss from Continuing Operations: \$6.5 million (improved from \$7.2 million).
• Income from Discontinued Operations: \$77.3 million, mainly the gain from the BioEnvelope sale.
• Total Net Income: \$70.8 million (compared to a net loss of \$9.1 million in Q4 2024).
• Adjusted EBITDA: Loss of \$4.2 million (vs. \$3.4 million in Q4 2024).
• Shares Outstanding: 42.8 million Class A, plus 4.5 million pre-funded warrants as of December 31, 2025.

Full Year 2025 Financial Results

• Net Sales: \$12.3 million (down from \$14.5 million in 2024 due to changes in distribution models).
• SimpliDerm Sales: \$9.1 million (down from \$11.6 million).
• Cardiovascular Sales: \$3.2 million (up from \$2.9 million).
• Gross Margin (GAAP): 53.7% (up from 46.4%).
• Adjusted Gross Margin (Non-GAAP): 62.4% (up from 53.9%).
• Total Operating Expenses: \$33.5 million (down from \$37.4 million).
• Net Loss from Continuing Operations: \$15.9 million (improved from \$45.3 million loss).
• Income from Discontinued Operations: \$69.3 million (BioEnvelope gain).
• Total Net Income: \$53.4 million (compared to a \$53.9 million net loss in 2024).
• Adjusted EBITDA: Loss of \$12.8 million (vs. \$11.2 million loss in 2024).

Balance Sheet and Liquidity

• Total Assets (as of Dec 31, 2025): \$62.4 million (up from \$36.1 million in 2024).
• Total Liabilities: \$34.7 million (down from \$82.4 million in 2024, reflecting debt repayment and improved financial position).
• Stockholders’ Equity: Positive \$27.7 million (up from a deficit of \$46.3 million).

Strategic Direction and Management Commentary

CEO Dr. Randy Mills emphasized that 2025 was the year Elutia validated its drug-eluting biologic platform, with robust market interest. The BioEnvelope divestiture eliminated debt and legacy distractions, positioning Elutia for high-velocity growth. Dr. Mills stated, “The current standard of care fails one in three women, and to us, that’s unacceptable. We are Ridiculously Relentless about ensuring that when a woman undergoes reconstruction, her recovery isn’t hijacked by a preventable complication, and we think NXT-41x will do just that.” The company is focused on ensuring mothers and daughters can thrive without compromise.

Other Noteworthy Items

• Conference Call Details: Elutia will host a call to discuss these results. The webcast and dial-in information are available on the company’s investor relations website.
• Non-GAAP Measures: The company provides adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA to give investors a clearer view of operating performance, excluding non-cash and one-time items.
• Forward-Looking Statements: Management provided guidance and risk disclosures, including risks related to product development, regulatory approval, and ongoing litigation related to legacy products (FiberCel and viable bone matrix).

What Shareholders Need to Know (Price-Sensitive Information)

• Regulatory Progress for NXT-41/NXT-41x: The NXT-41 FDA submission and anticipated clearances are critical milestones. Success or delays here could materially impact the company’s valuation and stock performance.
• BioEnvelope Divestiture: The \$88 million cash sale and associated gain have dramatically improved the balance sheet, eliminated debt, and provided growth capital, reducing financial risk and potentially enhancing shareholder value.
• Strategic Review of SimpliDerm: Any divestiture or partnership could further focus resources and unlock additional shareholder value or capital.
• Leadership Additions: The appointment of experienced commercial leadership signals readiness for a major product launch and potential sales ramp.
• Litigation and Legacy Risks: Shareholders should monitor ongoing litigation costs and risks, though the company reports progress in resolving these matters.

Conclusion

Elutia’s transformation in 2025—marked by the BioEnvelope divestiture, regulatory progress on NXT-41/NXT-41x, strengthened leadership, and improved financials—positions the company for significant potential growth and value creation. The upcoming FDA milestones, product launch preparations, and strategic reviews are all potentially share-price moving events that investors should watch closely.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should do their own research and consult a qualified financial advisor before making investment decisions. The information herein is based on the latest company filings and public disclosures as of March 11, 2026, and forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

View ELUTIA INC. Historical chart here